Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPMC NASDAQ:KNSA NASDAQ:LEGN NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMCBlueprint Medicines$129.46$125.78$73.04▼$129.65$8.36B0.891.55 million shsN/AKNSAKiniksa Pharmaceuticals International$31.98+5.7%$28.38$17.82▼$32.15$2.21B0.14611,693 shs1.07 million shsLEGNLegend Biotech$38.80-0.7%$36.34$27.34▼$59.62$7.18B0.261.37 million shs1.09 million shsROIVRoivant Sciences$11.31-0.4%$11.27$8.73▼$13.06$7.72B1.154.91 million shs2.91 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMCBlueprint Medicines0.00%0.00%+0.98%+23.72%+19.54%KNSAKiniksa Pharmaceuticals International+5.68%+21.46%+16.55%+15.66%+20.23%LEGNLegend Biotech-0.69%-10.52%+8.05%+16.97%-31.19%ROIVRoivant Sciences-0.44%-2.08%+3.10%-1.48%+4.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMCBlueprint Medicines1.0958 of 5 stars2.12.00.00.02.20.80.6KNSAKiniksa Pharmaceuticals International3.1269 of 5 stars3.53.00.00.02.53.30.6LEGNLegend Biotech3.5818 of 5 stars4.54.00.00.02.41.70.6ROIVRoivant Sciences1.8308 of 5 stars3.61.00.00.01.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1728.73% UpsideLEGNLegend Biotech 2.91Moderate Buy$73.3389.00% UpsideROIVRoivant Sciences 3.25Buy$16.5045.89% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, BPMC, ROIV, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $54.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.007/17/2025LEGNLegend BiotechJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/17/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/10/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.007/10/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$19.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.007/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/2/2025LEGNLegend BiotechUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.00 ➝ $54.006/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.006/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54KNSAKiniksa Pharmaceuticals International$423.24M5.51N/AN/A$6.78 per share4.72LEGNLegend Biotech$627.24M11.37N/AN/A$5.70 per share6.81ROIVRoivant Sciences$29.05M264.64N/AN/A$7.45 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%8/7/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04799.70127.92N/A0.90%1.05%0.80%N/ALEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/11/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/11/2025 (Estimated)Latest KNSA, BPMC, ROIV, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LEGNLegend Biotech-$0.18N/AN/AN/A$237.49 millionN/A8/11/2025Q1 2026ROIVRoivant Sciences-$0.23N/AN/AN/A$6.92 millionN/A8/7/2025Q2 2025BPMCBlueprint Medicines-$0.54N/AN/AN/A$171.34 millionN/A7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMCBlueprint MedicinesN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMCBlueprint Medicines1.012.802.75KNSAKiniksa Pharmaceuticals InternationalN/A3.573.43LEGNLegend Biotech0.305.205.07ROIVRoivant SciencesN/A33.4733.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMCBlueprint MedicinesN/AKNSAKiniksa Pharmaceuticals International53.95%LEGNLegend Biotech70.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBPMCBlueprint Medicines4.21%KNSAKiniksa Pharmaceuticals International53.48%LEGNLegend Biotech0.02%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableROIVRoivant Sciences860679.81 million626.10 millionOptionableKNSA, BPMC, ROIV, and LEGN HeadlinesRecent News About These CompaniesXTX Topco Ltd Boosts Position in Roivant Sciences Ltd. (NASDAQ:ROIV)July 30 at 5:27 AM | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $751,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)July 30 at 5:27 AM | marketbeat.comRoivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025July 28, 2025 | globenewswire.comGoldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ RatingJuly 25, 2025 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) CEO Sells $1,152,000.00 in StockJuly 25, 2025 | americanbankingnews.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Sells 100,000 Shares of StockJuly 24, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker Sells 100,000 SharesJuly 24, 2025 | insidertrades.comNew York State Common Retirement Fund Sells 28,400 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)July 24, 2025 | marketbeat.comMutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)July 20, 2025 | marketbeat.comCenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)July 16, 2025 | marketbeat.comBank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)July 15, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comRoivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?July 9, 2025 | marketbeat.comDAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)July 9, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement SystemJuly 9, 2025 | marketbeat.com'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five monthsJune 28, 2025 | msn.comRoivant Sciences’ president Venker sells $1.15 million in sharesJune 26, 2025 | investing.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in StockJune 25, 2025 | insidertrades.comRoivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment MosliciguatJune 24, 2025 | msn.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of StockJune 24, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, BPMC, ROIV, and LEGN Company DescriptionsBlueprint Medicines NASDAQ:BPMC$129.46 0.00 (0.00%) As of 07/18/2025Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Kiniksa Pharmaceuticals International NASDAQ:KNSA$31.98 +1.72 (+5.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$32.79 +0.81 (+2.54%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Legend Biotech NASDAQ:LEGN$38.80 -0.27 (-0.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$38.81 +0.01 (+0.03%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Roivant Sciences NASDAQ:ROIV$11.31 -0.05 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.04 -0.28 (-2.43%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
